-
1
-
-
34447520330
-
Anticancer carrier-linked prodrugs in clinical trials
-
Kratz, F., Abu Ajaj, K., and Warnecke, A. (2007) Anticancer carrier-linked prodrugs in clinical trials. Expert Opin. Invest. Drugs 16, 1037-1058.
-
(2007)
Expert Opin. Invest. Drugs
, vol.16
, pp. 1037-1058
-
-
Kratz, F.1
Abu Ajaj, K.2
Warnecke, A.3
-
2
-
-
39349084237
-
Prodrug strategies in anticancer chemotherapy
-
Kratz, F., Muller, I. A., Ryppa, C., and Warnecke, A. (2008) Prodrug strategies in anticancer chemotherapy. ChemMedChem 3, 20-53.
-
(2008)
ChemMedChem 3
, pp. 20-53
-
-
Kratz, F.1
Muller, I.A.2
Ryppa, C.3
Warnecke, A.4
-
3
-
-
0037068501
-
Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: Inhibition of aggregation by methoxytriethyleneglycol chains
-
King, H. D., Dubowchik, G. M., Mastalerz, H., Willner, D., Hofstead, S. J., Firestone, R. A., Lasch, S. J., and Trail, P. A. (2002) Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyleneglycol chains. J. Med. Chem. 45, 4336-4343.
-
(2002)
J. Med. Chem
, vol.45
, pp. 4336-4343
-
-
King, H.D.1
Dubowchik, G.M.2
Mastalerz, H.3
Willner, D.4
Hofstead, S.J.5
Firestone, R.A.6
Lasch, S.J.7
Trail, P.A.8
-
4
-
-
0036579776
-
Paclitaxel delivery systems: The use of amino acid linkers in the conjugation of paclitaxel with carboxymethyldextran to create prodrugs
-
Sugahara, S., Kajiki, M., Kuriyama, H., and Kobayashi, T. R. (2002) Paclitaxel delivery systems: the use of amino acid linkers in the conjugation of paclitaxel with carboxymethyldextran to create prodrugs. Biol Pharm. Bull. 25, 632-641.
-
(2002)
Biol Pharm. Bull
, vol.25
, pp. 632-641
-
-
Sugahara, S.1
Kajiki, M.2
Kuriyama, H.3
Kobayashi, T.R.4
-
5
-
-
33645984262
-
Prodrugs of anthracyclines in cancer chemotherapy
-
Kratz, F., Warnecke, A., Schmid, B., Chung, D. E., and Gitzel, M. (2006) Prodrugs of anthracyclines in cancer chemotherapy. Curr. Med. Chem. 13, 763-771.
-
(2006)
Curr. Med. Chem
, vol.13
, pp. 763-771
-
-
Kratz, F.1
Warnecke, A.2
Schmid, B.3
Chung, D.E.4
Gitzel, M.5
-
6
-
-
0029617286
-
Schedule-dependent interaction between paclitaxel and doxorubicin in human cancer cell lines in vitro
-
Akutsu, M., Kano, Y., Tsunoda, S., Suzuki, K., Yazawa, Y., and Miura, Y. (1995) Schedule-dependent interaction between paclitaxel and doxorubicin in human cancer cell lines in vitro. Eur. J. Cancer 31A, 2341-2346.
-
(1995)
Eur. J. Cancer
, vol.31 A
, pp. 2341-2346
-
-
Akutsu, M.1
Kano, Y.2
Tsunoda, S.3
Suzuki, K.4
Yazawa, Y.5
Miura, Y.6
-
7
-
-
0027753079
-
Characteristics of the combination paclitaxel plus doxorubicin in breast cancer cell lines analyzed with the ATP-cell viability assay
-
Koechli, O. R., Sevin, B. U., Perras, J. P., Chou, T. C., Angioli, R., Steren, A., Untch, M., and Averette, H. E. (1993) Characteristics of the combination paclitaxel plus doxorubicin in breast cancer cell lines analyzed with the ATP-cell viability assay. Breast Cancer Res. Treat. 28, 21-27.
-
(1993)
Breast Cancer Res. Treat
, vol.28
, pp. 21-27
-
-
Koechli, O.R.1
Sevin, B.U.2
Perras, J.P.3
Chou, T.C.4
Angioli, R.5
Steren, A.6
Untch, M.7
Averette, H.E.8
-
8
-
-
33646872893
-
A phase I study of paclitaxel/ doxorubicin/ thalidomide in patients with androgen- independent prostate cancer
-
Amato, R. J., and Sarao, H. (2006) A phase I study of paclitaxel/ doxorubicin/ thalidomide in patients with androgen- independent prostate cancer. Clin. Genitourin Cancer 4, 281-286.
-
(2006)
Clin. Genitourin Cancer
, vol.4
, pp. 281-286
-
-
Amato, R.J.1
Sarao, H.2
-
9
-
-
2142708274
-
Gemcitabine, anthracycline, and taxane combinations for advanced breast cancer
-
Zielinski, C. C. (2003) Gemcitabine, anthracycline, and taxane combinations for advanced breast cancer. Oncology (Williston Park) 17, 36-40.
-
(2003)
Oncology (Williston Park)
, vol.17
, pp. 36-40
-
-
Zielinski, C.C.1
-
10
-
-
42949158252
-
Taxanes alone or in combination with anthracyclines as firstline therapy of patients with metastatic breast cancer
-
Piccart-Gebhart, M. J., Burzykowski, T., Buyse, M., Sledge, G., Carmichael, J., Luck, H. J., Mackey, J. R., Nabholtz, J. M., Paridaens, R., Biganzoli, L., Jassem, J., Bontenbal, M., Bonneterre, J., Chan, S., Basaran, G. A., and Therasse, P. (2008) Taxanes alone or in combination with anthracyclines as firstline therapy of patients with metastatic breast cancer. J. Clin. Oncol. 26, 1980-1986.
-
(2008)
J. Clin. Oncol
, vol.26
, pp. 1980-1986
-
-
Piccart-Gebhart, M.J.1
Burzykowski, T.2
Buyse, M.3
Sledge, G.4
Carmichael, J.5
Luck, H.J.6
Mackey, J.R.7
Nabholtz, J.M.8
Paridaens, R.9
Biganzoli, L.10
Jassem, J.11
Bontenbal, M.12
Bonneterre, J.13
Chan, S.14
Basaran, G.A.15
Therasse, P.16
-
11
-
-
33645757580
-
Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: A translational research experience
-
Passardi, A., Massa, I., Zoli, W., Gianni, L., Milandri, C., Zumaglini, F., Nanni, O., Maltoni, R., Frassineti, G. L., and Amadori, D. (2006) Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience. BMC Cancer 6, 76.
-
(2006)
BMC Cancer
, vol.6
, pp. 76
-
-
Passardi, A.1
Massa, I.2
Zoli, W.3
Gianni, L.4
Milandri, C.5
Zumaglini, F.6
Nanni, O.7
Maltoni, R.8
Frassineti, G.L.9
Amadori, D.10
-
12
-
-
33846813876
-
Phase I trial of paclitaxel, doxorubicin, and carboplatin (TAC) for the treatment of endometrial cancer
-
Shimada, M., Kigawa, J., Terakawa, N., Yoshizaki, A., Shoji, T., Suzuki, M., Hatae, M., Tsuda, H., Ohwada, M., and Sugiyama, T. (2007) Phase I trial of paclitaxel, doxorubicin, and carboplatin (TAC) for the treatment of endometrial cancer. Int. J. Gynecol Cancer 17, 210-214.
-
(2007)
Int. J. Gynecol Cancer
, vol.17
, pp. 210-214
-
-
Shimada, M.1
Kigawa, J.2
Terakawa, N.3
Yoshizaki, A.4
Shoji, T.5
Suzuki, M.6
Hatae, M.7
Tsuda, H.8
Ohwada, M.9
Sugiyama, T.10
-
13
-
-
0037325515
-
Synthesis and in vitro efficacy of acid-sensitive poly(ethylene glycol) paclitaxel conjugates
-
Rodrigues, P. C. A., Scheuermann, K., Stockmar, C., Maier, G., Fiebig, H. H., Unger, C., Mülhaupt, R., and Kratz, F. (2003) Synthesis and in vitro efficacy of acid-sensitive poly(ethylene glycol) paclitaxel conjugates. Bioorg. Med. Chem. Lett. 13, 355-360.
-
(2003)
Bioorg. Med. Chem. Lett
, vol.13
, pp. 355-360
-
-
Rodrigues, P.C.A.1
Scheuermann, K.2
Stockmar, C.3
Maier, G.4
Fiebig, H.H.5
Unger, C.6
Mülhaupt, R.7
Kratz, F.8
-
14
-
-
0019453510
-
A novel connector linkage applicable in prodrug design
-
Carl, P. L., Chakravarty, P. K., and Katzenellenbogen, J. A. (1981) A novel connector linkage applicable in prodrug design. J. Med. Chem. 24, 479-480.
-
(1981)
J. Med. Chem
, vol.24
, pp. 479-480
-
-
Carl, P.L.1
Chakravarty, P.K.2
Katzenellenbogen, J.A.3
-
15
-
-
34347354414
-
Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: Synthesis and antitumor efficacy
-
Schmid, B., Chung, D. E., Warnecke, A., Fichtner, I., and Kratz, F. (2007) Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy. Bioconjugate Chem. 18, 702-716.
-
(2007)
Bioconjugate Chem
, vol.18
, pp. 702-716
-
-
Schmid, B.1
Chung, D.E.2
Warnecke, A.3
Fichtner, I.4
Kratz, F.5
-
16
-
-
0036074253
-
Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: Model studies of enzymatic drug release and antigen-specific in vitro anticancer activity
-
Dubowchik, G. M., Firestone, R. A., Padilla, L., Willner, D., Hofstead, S. J., Mosure, K., Knipe, J. O., Lasch, S. J., and Trail, P. A. (2002) Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjugate Chem. 13, 855-869.
-
(2002)
Bioconjugate Chem
, vol.13
, pp. 855-869
-
-
Dubowchik, G.M.1
Firestone, R.A.2
Padilla, L.3
Willner, D.4
Hofstead, S.J.5
Mosure, K.6
Knipe, J.O.7
Lasch, S.J.8
Trail, P.A.9
-
17
-
-
0342314489
-
A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy
-
Kratz, F., Mueller-Driver, R., Hofmann, I., Drevs, J., and Unger, C. (2000) A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy. J. Med. Chem. 43, 1253-1256.
-
(2000)
J. Med. Chem
, vol.43
, pp. 1253-1256
-
-
Kratz, F.1
Mueller-Driver, R.2
Hofmann, I.3
Drevs, J.4
Unger, C.5
-
18
-
-
0037028050
-
Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives: Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound
-
Kratz, F., Warnecke, A., Scheuermann, K., Stockmar, C., Schwab, J., Lazar, P., Druckes, P., Esser, N., Drevs, J., Rognan, D., Bissantz, C., Hinderung, C., Folkers, G., Fichtner, I., and Unger, C. (2002) Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives: improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound. J. Med. Chem. 45, 5523-5533.
-
(2002)
J. Med. Chem
, vol.45
, pp. 5523-5533
-
-
Kratz, F.1
Warnecke, A.2
Scheuermann, K.3
Stockmar, C.4
Schwab, J.5
Lazar, P.6
Druckes, P.7
Esser, N.8
Drevs, J.9
Rognan, D.10
Bissantz, C.11
Hinderung, C.12
Folkers, G.13
Fichtner, I.14
Unger, C.15
-
19
-
-
0042173127
-
A new approach for the treatment of malignant melanoma: Enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2
-
Mansour, A. M., Drevs, J., Esser, N., Hamada, F. M., Badary, O. A., Unger, C., Fichtner, I., and Kratz, F. (2003) A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Cancer Res. 63, 4062-4066.
-
(2003)
Cancer Res
, vol.63
, pp. 4062-4066
-
-
Mansour, A.M.1
Drevs, J.2
Esser, N.3
Hamada, F.M.4
Badary, O.A.5
Unger, C.6
Fichtner, I.7
Kratz, F.8
-
20
-
-
0032421248
-
Serum proteins as drug carriers of anticancer agents: A review
-
Kratz, F., and Beyer, U. (1998) Serum proteins as drug carriers of anticancer agents: a review. Drug Delivery 5, 281-299.
-
(1998)
Drug Delivery
, vol.5
, pp. 281-299
-
-
Kratz, F.1
Beyer, U.2
-
21
-
-
0034000453
-
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review
-
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., and Hori, K. (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Controlled Release 65, 271-284.
-
(2000)
J. Controlled Release
, vol.65
, pp. 271-284
-
-
Maeda, H.1
Wu, J.2
Sawa, T.3
Matsumura, Y.4
Hori, K.5
-
22
-
-
34249980937
-
DOXO-EMCH (INNO-206): The first albumin-binding prodrug of doxorubicin to enter clinical trials
-
Kratz, F. (2007) DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials. Expert Opin. Investig. Drugs 16, 855-66.
-
(2007)
Expert Opin. Investig. Drugs
, vol.16
, pp. 855-866
-
-
Kratz, F.1
-
23
-
-
27644436770
-
Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen
-
Kratz, F., Mansour, A., Soltau, J., Warnecke, A., Fichtner, I., Unger, C., and Drevs, J. (2005) Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen. Arch. Pharm. (Weinheim) 338, 462-412.
-
(2005)
Arch. Pharm. (Weinheim)
, vol.338
, pp. 462-412
-
-
Kratz, F.1
Mansour, A.2
Soltau, J.3
Warnecke, A.4
Fichtner, I.5
Unger, C.6
Drevs, J.7
-
24
-
-
33747339731
-
Development of a novel albumin-binding prodrug that is cleaved by urokinase-type-plasminogen activator (uPA)
-
Chung, D. E., and Kratz, F. (2006) Development of a novel albumin-binding prodrug that is cleaved by urokinase-type-plasminogen activator (uPA). Bioorg. Med. Chem. Lett. 16, 5157-5163.
-
(2006)
Bioorg. Med. Chem. Lett
, vol.16
, pp. 5157-5163
-
-
Chung, D.E.1
Kratz, F.2
-
25
-
-
38749154289
-
Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP)
-
Graeser, R., Chung, D. E., Esser, N., Moor, S., Schachtele, C., Unger, C., and Kratz, F. (2008) Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP). Int. J. Cancer 122, 1145-1154.
-
(2008)
Int. J. Cancer
, vol.122
, pp. 1145-1154
-
-
Graeser, R.1
Chung, D.E.2
Esser, N.3
Moor, S.4
Schachtele, C.5
Unger, C.6
Kratz, F.7
-
26
-
-
47949115836
-
Targeted drug delivery by in vivo coupling to endogenous albumin: An albumin-binding prodrug of methotrexate (MTX) is better than MTX in the treatment of murine collagen-induced arthritis
-
Fiehn, C., Kratz, F., Sass, G., Muller-Ladner, U., and Neumann, E. (2008) Targeted drug delivery by in vivo coupling to endogenous albumin: an albumin-binding prodrug of methotrexate (MTX) is better than MTX in the treatment of murine collagen-induced arthritis. Ann. Rheum. Dis. 67, 1188-1191.
-
(2008)
Ann. Rheum. Dis
, vol.67
, pp. 1188-1191
-
-
Fiehn, C.1
Kratz, F.2
Sass, G.3
Muller-Ladner, U.4
Neumann, E.5
-
27
-
-
34548067350
-
Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B
-
Warnecke, A., Fichtner, I., Sass, G., and Kratz, F. (2007) Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B. Arch. Pharm. (Weinheim) 340, 389-395.
-
(2007)
Arch. Pharm. (Weinheim)
, vol.340
, pp. 389-395
-
-
Warnecke, A.1
Fichtner, I.2
Sass, G.3
Kratz, F.4
-
28
-
-
0035896201
-
Acid-labile protecting groups for the synthesis of lipidated peptides
-
Kadereit, D., Deck, P., Heinemann, I., and Waldmann, H. (2001) Acid-labile protecting groups for the synthesis of lipidated peptides. Chem. Eur. J. 7, 1184-1193.
-
(2001)
Chem. Eur. J
, vol.7
, pp. 1184-1193
-
-
Kadereit, D.1
Deck, P.2
Heinemann, I.3
Waldmann, H.4
-
29
-
-
0030792535
-
Monomethoxytrityl (MMT) as a versatile amino protecting group for complex prodrugs of anticancer compounds sensitive to strong acids, bases and nucleophiles
-
Dubowchik, G. M., and Radia, S. (1997) Monomethoxytrityl (MMT) as a versatile amino protecting group for complex prodrugs of anticancer compounds sensitive to strong acids, bases and nucleophiles. Tetrahedron Lett. 38, 5257-5260.
-
(1997)
Tetrahedron Lett
, vol.38
, pp. 5257-5260
-
-
Dubowchik, G.M.1
Radia, S.2
-
30
-
-
58849118375
-
-
Abu Ajaj, K., and Kratz, F. (2009) Development of dual-acting prodrugs for circumventing multidrug resistance in breast cancer. Bioorg. Med. Chem. Lett., online, DOI: 10.1016/j.bmcl.2008.11.063.
-
Abu Ajaj, K., and Kratz, F. (2009) Development of dual-acting prodrugs for circumventing multidrug resistance in breast cancer. Bioorg. Med. Chem. Lett., online, DOI: 10.1016/j.bmcl.2008.11.063.
-
-
-
|